BPTH Bio-Path Holdings Inc

Price (delayed)

$3.92

Market cap

$28.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.61

Enterprise value

$7.12M

Bio-Path is a biotechnology company developing DNAbilizeĀ®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead ...

Highlights
Bio-Path Holdings's EPS has increased by 31% YoY but it has decreased by 3.9% from the previous quarter
Bio-Path Holdings's debt has increased by 26% QoQ but it has decreased by 3.6% YoY
The quick ratio has contracted by 45% from the previous quarter and by 33% YoY
BPTH's equity is down by 29% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of BPTH
Market
Shares outstanding
7.16M
Market cap
$28.07M
Enterprise value
$7.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$11.35M
EBITDA
-$11.18M
Free cash flow
-$10.89M
Per share
EPS
-$1.61
Free cash flow per share
-$1.52
Book value per share
$3.12
Revenue per share
$0
TBVPS
$3.36
Balance sheet
Total assets
$24.08M
Total liabilities
$1.76M
Debt
$296,000
Equity
$22.32M
Working capital
$22.04M
Liquidity
Debt to equity
0.01
Current ratio
15.06
Quick ratio
13.55
Net debt/EBITDA
1.87
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-40.4%
Return on equity
-42.5%
Return on invested capital
-507.9%
Return on capital employed
-50.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPTH stock price

How has the Bio-Path Holdings stock price performed over time
Intraday
0%
1 week
3.7%
1 month
20.99%
1 year
-43.76%
YTD
3.98%
QTD
2.08%

Financial performance

How have Bio-Path Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.35M
Net income
-$11.35M
Gross margin
N/A
Net margin
N/A
The operating income is down by 13% year-on-year and by 9% since the previous quarter
BPTH's net income is down by 13% year-on-year and by 9% since the previous quarter

Growth

What is Bio-Path Holdings's growth rate over time

Valuation

What is Bio-Path Holdings stock price valuation
P/E
N/A
P/B
1.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Bio-Path Holdings's EPS has increased by 31% YoY but it has decreased by 3.9% from the previous quarter
The stock's price to book (P/B) is 40% less than its 5-year quarterly average of 2.1 and 3.1% less than its last 4 quarters average of 1.3
BPTH's equity is down by 29% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Bio-Path Holdings business performance
The return on equity has grown by 20% year-on-year but it has declined by 18% since the previous quarter
BPTH's return on assets is down by 17% since the previous quarter but it is up by 17% year-on-year
BPTH's ROIC is up by 11% YoY but it is down by 3.1% QoQ

Dividends

What is BPTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPTH.

Financial health

How did Bio-Path Holdings financials performed over time
Bio-Path Holdings's total liabilities has surged by 59% QoQ and by 2.1% YoY
The quick ratio has contracted by 45% from the previous quarter and by 33% YoY
Bio-Path Holdings's debt is 99% lower than its equity
BPTH's equity is down by 29% year-on-year and by 12% since the previous quarter
Bio-Path Holdings's debt has increased by 26% QoQ but it has decreased by 3.6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.